Kadimastem Ltd.

Kadimastem is excited to report that it has completed another stage towards the merger with NLS Pharmaceutics, which has Regained Full Compliance with Nasdaq Listing Requirements This constitutes a significant condition for the completion of the merger transaction. Thus, one of the most significant conditions for the merger transaction has been met! #merger #NASDAQ #BIOTECH #innovation #technology #biotechnology

In local communities all over the nation people come together to #run, #walk and #support #ALS it is still so important to continue to fight for a #cure for this horrific disease! Find out how you can support ALS in your local community through your local ALS chapter The ALS Association

Kadimastem Ltd. is excited to update on the progress of our huge merger deal with the biopharma company NLS, this will bring Kadimastem forward to the Nasdaq In preparation for the merger with the Swiss biopharma company NLS Pharmaceutics AG, which is traded on Nasdaq, Kadimastem announces that NLS meets the trading conditions and has completed a capital raising of 3.2 million dollars.

Kadimastem Ltd. and NLS Pharmaceutics Announce Binding Term Sheet to Merge! The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and focused on advancing Kadimastem’s allogeneic cell therapy platform Each of Kadimastem and NLS Pharmaceutics has received commitments of support for the transaction from shareholders representing more than 40% of their respective outstanding shares

The World Prestigious Diabetes Research Institute Foundation, University of Miami, Announces Kadimastem's Joint Project with iTolerance, Inc. as Breakthrough Transplantation Approach for the Treatment of Type 1 Diabetes The results were presented at the 84th scientific conference of the American Diabetes Association (ADA) #T1D #diabetescure #diabetestreatment #celltherapy #biotechnology

Kadimastem LTD is attending the ADA 84th Scientific Sessions happening June 21–24 in Orlando, FL! It is the largest, most exciting diabetes conference and hope to see you there! https://bit.ly/3yI8BRT @AmDiabetesAssn #DiabetesAwareness #RegenerativeCellTherapy #T1D #celltherapy #diabetescure

Kadimastem Ltd. Takes Another Step Towards Signing the #Merger Agreement with #nasdaq Listed IMCC #mergersandacquisitions

Kadimastem makes move towards #NASDAQ: Company Signs a MOU to Merge with a Company traded on the Nasdaq! #capitalmarkets #investment #merger

Kadimastem Ltd. Receives #patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for #diabetes in India   The patent approval in India strengthens the company’s global position in the diabetes field

A peer reviewed article on Kadimastem's AstroRx® Cryopreserved off the Shelf Cell Product for the Treatment of ALS was Published in the Journal of Clinical Toxicology The publication presents the development and preclinical safety of Kadimastem's off the shelf AstroRx ("thaw to inject") cell product in comprehensive toxicity studies